SCHEMBL5583246

SCHEMBL5583246

CN(C)C=C1CCCc2c([nH]c3ccccc23)C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.56
RAB9A P51151 7/20 0.56
MEN1 O00255 6/20 0.56
KMT2A Q03164 6/20 0.56
HSD17B10 Q99714 2/20 0.56
MAPT P10636 7/20 0.54
ALDH1A1 P00352 6/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
POLB P06746 3/20 0.54
LMNA P02545 3/20 0.54
NPC1 O15118 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.52
HTT P42858 2/20 0.47
MAPK1 P28482 1/20 0.47
HPGD P15428 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
ADRB2 P07550 1/20 0.43
HTR1A P08908 1/20 0.43
HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14366541 1.00 KDM4E (0.56) KDM4ERAB9AMEN1KMT2AHSD17B10
SCHEMBL5583245 1.00 KDM4E (0.56) KDM4ERAB9AMEN1KMT2AHSD17B10
SCHEMBL14366543 0.76 KDM4E (0.66) KDM4ERAB9AMEN1KMT2AHSD17B10
SCHEMBL5583264 0.76 KDM4E (0.66) KDM4ERAB9AMEN1KMT2AHSD17B10
SCHEMBL5583263 0.76 KDM4E (0.66) KDM4ERAB9AMEN1KMT2AHSD17B10
SCHEMBL13925707 0.75 MAPT (0.53) KDM4ERAB9AMEN1KMT2AHSD17B10
SCHEMBL14366545 0.74 KDM4E (0.69) KDM4ERAB9AMEN1KMT2AHSD17B10
SCHEMBL5583198 0.74 KDM4E (0.69) KDM4ERAB9AMEN1KMT2AHSD17B10
SCHEMBL5583200 0.74 KDM4E (0.69) KDM4ERAB9AMEN1KMT2AHSD17B10
SCHEMBL4021839 0.73 HSD17B10 (1.00) KDM4ERAB9AMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer IGF1R, KDR, ERBB2 KDM4E 1419/4885RAB9A 4338/4885MEN1 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.